MX2020003810A - Vacuna contra la periodontitis y composiciones relacionadas y metodos de uso. - Google Patents

Vacuna contra la periodontitis y composiciones relacionadas y metodos de uso.

Info

Publication number
MX2020003810A
MX2020003810A MX2020003810A MX2020003810A MX2020003810A MX 2020003810 A MX2020003810 A MX 2020003810A MX 2020003810 A MX2020003810 A MX 2020003810A MX 2020003810 A MX2020003810 A MX 2020003810A MX 2020003810 A MX2020003810 A MX 2020003810A
Authority
MX
Mexico
Prior art keywords
antigen sequence
sequence
rgpa
gingipain
immunogenic
Prior art date
Application number
MX2020003810A
Other languages
English (en)
Spanish (es)
Inventor
Jeffery Fairman
Original Assignee
Vaxcyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxcyte Inc filed Critical Vaxcyte Inc
Publication of MX2020003810A publication Critical patent/MX2020003810A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2020003810A 2017-10-12 2018-10-11 Vacuna contra la periodontitis y composiciones relacionadas y metodos de uso. MX2020003810A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762571582P 2017-10-12 2017-10-12
PCT/US2018/055496 WO2019075260A1 (en) 2017-10-12 2018-10-11 VACCINE AGAINST PERIODONTITIS AND ASSOCIATED COMPOSITIONS AND METHOD OF USE

Publications (1)

Publication Number Publication Date
MX2020003810A true MX2020003810A (es) 2020-08-13

Family

ID=64110091

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003810A MX2020003810A (es) 2017-10-12 2018-10-11 Vacuna contra la periodontitis y composiciones relacionadas y metodos de uso.

Country Status (14)

Country Link
US (3) US10835590B2 (enExample)
EP (1) EP3694547A1 (enExample)
JP (2) JP7258870B2 (enExample)
KR (2) KR102530966B1 (enExample)
CN (1) CN111225684A (enExample)
AU (1) AU2018347511A1 (enExample)
CA (1) CA3078630A1 (enExample)
EA (1) EA202090908A1 (enExample)
IL (1) IL273690A (enExample)
MA (1) MA50363A (enExample)
MX (1) MX2020003810A (enExample)
PH (1) PH12020550239A1 (enExample)
SG (1) SG11202003147XA (enExample)
WO (1) WO2019075260A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111225684A (zh) 2017-10-12 2020-06-02 Sutrovax公司 牙周炎疫苗和相关组合物及使用方法
US12637503B2 (en) 2020-11-03 2026-05-26 K-Bio Investment, Llc Antigen-binding molecules that bind to Porphyromonas gingivalis
WO2025019900A1 (en) * 2023-07-26 2025-01-30 Denteric Pty Ltd Chimeric protein vaccine
CN116751292B (zh) * 2023-07-31 2024-05-14 河南大学 牙龈卟啉单胞菌Mfa1单克隆抗体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59128338A (ja) 1982-12-08 1984-07-24 Kitasato Inst:The 歯周炎予防用ワクチン及びその製法
WO1994028014A2 (en) 1993-05-28 1994-12-08 Chiron Corporation Peptide inhibitors of urokinase receptor activity
AUPN627595A0 (en) * 1995-10-30 1995-11-23 University Of Melbourne, The Diagnostics and treatments of periodontal disease
JP2000507245A (ja) 1996-03-22 2000-06-13 ユニバーシティー オブ ジョージア リサーチ ファウンデーション,インコーポレイテッド Porphyromonas gingivalisペプチドを含む免疫原性組成物および方法
US6833262B1 (en) 1999-04-21 2004-12-21 University Of Georgia Research Foundation, Inc. Polypeptide having amidolytic activity for a serpin
AUPQ065299A0 (en) 1999-05-28 1999-06-24 University Of Sydney, The A method of prophylaxis and treatment and agents useful for same
AUPQ485999A0 (en) * 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
US7378101B2 (en) 2001-12-21 2008-05-27 Pfizer, Inc. Vaccine for periodontal disease
GB0411150D0 (en) 2004-05-19 2004-06-23 Queen Mary & Westfield College Vaccine
MX2012001495A (es) 2009-08-02 2012-08-03 Sanofi Pasteur Ltd Polipeptidos de porphyromonas gingivalis.
AU2011214908A1 (en) 2010-02-12 2012-09-20 Sydney West Area Health Services (Swahs) Protein domains and uses therefor
WO2011130544A2 (en) 2010-04-14 2011-10-20 Sutro Biopharma, Inc. Monitoring a dynamic system by liquid chromatography-mass spectrometry
WO2014058830A1 (en) 2012-10-12 2014-04-17 Sutro Biopharma, Inc. Proteolytic inactivation of select proteins in bacterial extracts for improved expression
EP3365027B1 (en) * 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
CN111225684A (zh) 2017-10-12 2020-06-02 Sutrovax公司 牙周炎疫苗和相关组合物及使用方法

Also Published As

Publication number Publication date
US11701414B2 (en) 2023-07-18
CA3078630A1 (en) 2019-04-18
WO2019075260A1 (en) 2019-04-18
EA202090908A1 (ru) 2020-10-29
IL273690A (en) 2020-05-31
US20190192645A1 (en) 2019-06-27
JP2020536925A (ja) 2020-12-17
US20240131134A1 (en) 2024-04-25
PH12020550239A1 (en) 2021-02-15
US20210361756A1 (en) 2021-11-25
JP7258870B2 (ja) 2023-04-17
KR102530966B1 (ko) 2023-05-15
KR20230066660A (ko) 2023-05-16
MA50363A (fr) 2020-08-19
AU2018347511A1 (en) 2020-05-21
EP3694547A1 (en) 2020-08-19
US10835590B2 (en) 2020-11-17
KR20200070302A (ko) 2020-06-17
AU2018347511A8 (en) 2020-06-11
CN111225684A (zh) 2020-06-02
BR112020006500A2 (pt) 2020-10-13
US20240226259A9 (en) 2024-07-11
SG11202003147XA (en) 2020-05-28
JP2023098935A (ja) 2023-07-11
US12121575B2 (en) 2024-10-22

Similar Documents

Publication Publication Date Title
PH12020550239A1 (en) Periodontitis vaccine and related compositions and methods of use
EA201692315A1 (ru) Составы и способы обработки кератина
MX2018014573A (es) Vacuna contra el virus del zika.
CL2018003178A1 (es) Composición farmacéutica
MX2023003875A (es) Formulacion de una vacuna peptidica.
BR112022005687A2 (pt) Vacinas contra o hbv e métodos para tratar o hbv
MX2018014631A (es) Formulacion de neurotoxina.
MX2015009963A (es) Metodos y composición farmacéutica para el tratamiento y la prevención de cardiomiopatía debido a falta de energía.
AR081809A1 (es) Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas
BR112017000313A2 (pt) sistema para o fornecimento de uma composição para tratamento bucal, composição para tratamento bucal, método para administrar uma composição para tratamento bucal
CL2020001821A1 (es) Formulación de adenovirus del grupo b.
MX2022003758A (es) Composiciones para el cuidado bucal que comprenden acido beta de lupulo y aminoacido.
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
MX2021004907A (es) Vacuna de ibv 4/91 con proteina espicular heterologa.
MX2021005910A (es) Formulacion de proteina de alta concentracion.
MX2021013018A (es) Formulacion de arnm.
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
CO2025016879A2 (es) Composiciones para el uso en el tratamiento del acné
MX2024005962A (es) Composiciones de proteínas de fusión inmunogénicas y métodos de uso de estas
CL2019003011A1 (es) Composiciones para el cuidado bucal a base de oxido de cinc y fosfato de dihidrógeno de calcio.
CL2024000740A1 (es) Composiciones de gel inmunógenas
AR083006A1 (es) Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
EA202290122A1 (ru) Фармацевтические композиции в форме геля, содержащие ксилоглюкан и спирты, для регулируемого высвобождения активных ингредиентов
CU20200097A7 (es) Composición de vacuna contra la hepatitis b, proceso de obtención de dicha composición y sistema de rinovacunación para prevenir y tratar la hepatitis b
AR107295A1 (es) Administración intradérmica de una composición de inmunoglobulina g